All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

In 5-Year Span of FDA Accelerated Approvals in Cancer, 43% Show Confirmatory Clinical Benefit

April 7th 2024

Fifty-seven percent of drugs granted accelerated approval for a cancer indication failed to show clinical benefit in confirmatory studies.

Personalized Cancer Vaccine Leads to Delays in Pancreatic Cancer Recurrence

April 7th 2024

Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.

Cadonilimab Plus Oxaliplatin and Capecitabine Offers Survival Benefit in Gastric/GEJ Cancer

April 7th 2024

Cadonilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.

Experimental MDS Drug Appears Beneficial for Some

April 7th 2024

In a new phase 3 clinical trial, imetelstat demonstrated clear advantages for patients who have failed or are ineligible for other therapies.

Fox Chase Surgeon Sanjay S. Reddy to Participate in Inaugural Society of Surgical Oncology Career Catalyst Mentorship Program

April 6th 2024

Sanjay S. Reddy, MD, FACS, of Fox Chase Cancer Center was recently chosen as a participant in the Society of Surgical Oncology’s inaugural Career Catalyst Mentorship Program.

Sotomayor Elucidates Updates Including ADC and Bispecific Antibody Combinations in Hematology

April 6th 2024

Eduardo M. Sotomayor, MD, discusses updates in the treatment of hematologic malignancies, highlighting research on antibody-drug conjugate and bispecific antibody combinations.

FDA Approves Cilta-Cel for R/R Multiple Myeloma After at Least One Prior Line of Therapy

April 6th 2024

The FDA has approved cilta-cel for select patients with relapsed/refractory multiple myeloma who have received at least 1 line of therapy, and who are lenalidomide refractory.

Iglesia Spotlights the Current Complexities of Treatment Sequencing in Advanced HCC

April 5th 2024

Michael Iglesia, MD, PhD, discusses the effects of the phase 3 CELESTIAL trial on treatment sequencing strategies in advanced hepatocellular carcinoma.

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2+ Solid Tumors

April 5th 2024

The FDA granted accelerated approval to trastuzumab deruxtecan for pretreated, unresectable or metastatic HER2-positive solid tumors.

Patient Selection Key for Focal Therapy in Intermediate Prostate Cancer

April 5th 2024

Ruben Olivares, MD, discusses the integration of focal therapy in the treatment of patients with intermediate prostate cancer.

Gita Suneja Named Senior Director of Programs to Enhance Diversity

April 5th 2024

Gita Suneja, MD, MS, has been named the senior director of Programs to Enhance Diversity at Huntsman Cancer Institute.

Phase 2 Data Support Use of RNX-051 in Cancerous and Precancerous CRC

April 5th 2024

RNX-051 displays impact on bacterial biomass in patients with right-sided colorectal cancer and right-sided colon polyps/adenomas.

Consolidation Durvalumab Generates Survival Benefit in LS-SCLC

April 5th 2024

Durvalumab monotherapy showed clinical benefit in limited-stage small cell lung cancer, according to data from the phase 3 ADRIATIC trial.

FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma

April 5th 2024

The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Afamitresgene Autoleucel Demonstrates Efficacy in Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

April 5th 2024

Afami-cel displayed activity in a heavily pretreated population of patients with advanced synovial sarcoma or myxoid round cell liposarcoma.

Revumenib Demonstrates Activity in Pediatric Patients With KMT2A+ Acute Leukemia

April 4th 2024

Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia.

Targeted Therapies Are Finding Their Footing in Hematologic Malignancies

April 4th 2024

Eduardo M. Sotomayor, MD, expands on the evolving treatment paradigm for hematologic malignancies, highlighting treatment with CAR T-cell therapy.

Tiwari Highlights Updates in HER2+ and HER2-Low Breast Cancer

April 4th 2024

Shruti Tiwari, MD, discusses treatment advances in HER2-positive and HER2-low breast cancer and looks ahead to the future of the space.

Neoadjuvant and Adjuvant Trials Could Continue to Individualize Treatment in MIBC

April 4th 2024

Bernard H. Bochner, MD, FACS, discusses updates in the treatment of muscle-invasive bladder cancer and ongoing trials in the space.

Expert Commentary: Insights into Cancer Mutation Patterns

April 4th 2024

Researchers at Rutgers Cancer Institute of New Jersey provided commentary on how changes in the structure of DNA influence the mutation patterns in cancer.